Quanta Dialysis Technologies

Quanta is a medical devices company enabling the future of kidney care, with a mission to bring to market solutions that improve the delivery of dialysis and help people live more freely.

Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system.

Quanta was founded in 2008 by John E. Milad. The company is based in Alcester, England, with operations in the US.

 

Quanta’s lead product, SC+, is a small and simple, powerful hemodialysis system designed to provide greater freedom and flexibility in the delivery of life sustaining dialysis treatments. In the US, SC+ is FDA cleared for use in acute and chronic care facilities, and in the UK, it is CE marked.

 

Quanta’s award-winning portable hemodialysis system SC+ is the only next-generation system that delivers the performance and dose equivalence of larger, traditional dialysis systems—with on-demand dialysate production and high dialysate flow rates—while also offering the portability, digital connectivity and ease-of-use of a next-generation dialysis device.

 

Quanta’s companion water purification module works with SC+ as an all-in-one mobile stack allowing dialysis treatments to be delivered in settings with just a standard water supply.

 

Quanta is backed by Glenview Capital, Novo Holdings, BlackRock, Eldridge, Sands Capital, Millennium Management, btov Partners, Wellington Partners, Seroba Life Sciences, and others. $245M in an oversubscribed and upsized Series D round on Jun 23, 2021. This brings Quanta's total funding to $351.7M to date. 

 

 

  • Year founded: 2008
  • Funding Info: $351.7M over 5 Rounds (Latest Funding Type: Series D)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Alcester
  • State: England
  • Country: United Kingdom
Related businesses